Quantitative SPECT/CT imaging of lead-212: a phantom study [PDF]
EJNMMI Physics, 2022 Background Lead-212 (212Pb) is a promising radionuclide for targeted therapy, as it decays to α-particle emitter bismuth-212 (212Bi) via β-particle emission. This extends the problematic short half-life of 212Bi.
Monika Kvassheim +2 more
doaj +5 more sources
Correction to: Quantitative SPECT/CT imaging of lead-212: a phantom study [PDF]
EJNMMI Physics, 2022 Correction to: Kvassheim, M., Revheim, ME.R. & Stokke, C. Quantitative SPECT/CT imaging of lead-212: a phantom study. EJNMMI Phys 9, 52 (2022).
Monika Kvassheim +2 more
doaj +4 more sources
Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors. [PDF]
Eur J Nucl Med Mol Imaging, 2023 Abstract Purpose The lead-203 (203Pb)/lead-212 (212Pb) elementally identical radionuclide pair has gained significant interest in the field of image-guided targeted alpha-particle therapy for cancer. Emerging evidence suggests that 212Pb-labeled peptide-based radiopharmaceuticals targeting somatostatin receptor subtype 2
Lee D +10 more
europepmc +3 more sources
Methodology for labeling proteins and peptides with lead-212 (212Pb). [PDF]
Nucl Med Biol, 2013 Alpha particles possess an exquisite degree of cytotoxicity when employed for targeted α-particle therapy (TAT) or radioimmunotherapy (RIT). (212)Pb, which acts as an in vivo generator of the α-emitting nuclide (212)Bi has shown great promise in pre-clinical studies when used to label the HER2 binding antibody, trastuzumab.
Baidoo KE, Milenic DE, Brechbiel MW.
europepmc +4 more sources
Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project [PDF]
PharmaceuticalsThis review comprehensively assesses the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment.
Valentina Di Iorio +14 more
doaj +2 more sources
Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors [PDF]
PharmaceuticalsBackground: α-emitting Peptide Receptor Radionuclide Therapy (α-PRRT) is emerging as a promising new generation of PRRT for neuroendocrine tumors (NETs), providing enhanced tumor cell cytotoxicity and reduced irradiation of adjacent healthy tissues due ...
Hannes Leupe +5 more
doaj +2 more sources
Lead-212 Radiopharmaceuticals for Receptor-Targeted Radionuclide Therapy [PDF]
Journal of Mazandaran University of Medical SciencesReceptor-targeted radionuclide therapy (RTRT) combines the power of particle-emitting radionuclides with the receptor-targeting capabilities of biomolecules, including antibodies and peptides.
Solmaz Mojarad-Jabali +1 more
doaj +1 more source
Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimization [PDF]
Nature CommunicationsThe rapid and economical synthesis of novel bioactive compounds remains a hurdle in drug discovery efforts. This study demonstrates an integrated medicinal chemistry workflow that effectively diversifies hit and lead structures, enabling an acceleration ...
David F. Nippa +23 more
doaj +2 more sources
Pharmaceutics, 2023 203Pb and 212Pb have emerged as promising theranostic isotopes for image-guided α-particle radionuclide therapy for cancers. Here, we report a cyclen-based Pb specific chelator (PSC) that is conjugated to tyr3-octreotide via a PEG2 linker (PSC-PEG-T ...
Mengshi Li +15 more
doaj +1 more source
Frontiers in Medicine, 2022 Osteosarcoma patients with overt metastases at primary diagnosis have a 5-year survival rate of less than 20%. TP-3 is a murine IgG2b monoclonal antibody with high affinity for an epitope residing on the p80 osteosarcoma cell surface membrane antigen ...
Anna Julie Kjøl Tornes +12 more
doaj +1 more source